High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Toshihide Horiuchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, 123-8558, Japan. Hauptthemen laut MEDLINE: Anilides, Pyridines, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objective
The real-world incidence of hepatic dysfunction after combination therapy with cabozantinib plus nivolumab (CABO+NIVO) in Japanese patients with metastatic renal cell carcinoma remains undetermined; hence, this study aimed to determine the incidence of hepatotoxicity in these patients.
Methods
A total of 48 patients treated with CABO+NIVO were enrolled in this study. Alanine aminotransferase (ALT) levels were used to evaluate liver dysfunction because of its liver specificity.
Results
ALT elevation of any grade was found in 30 patients (63%), and grade 3 elevation was found in eight patients (17%). No grade 4 or 5 elevations were observed. Female gender and a higher body mass index were independent predictive factors for ALT elevation. All patients were managed with dose reduction or interruption of cabozantinib and concomitant use of hepatoprotective agents without high-dose corticosteroids. Of the seven patients that underwent cabozantinib rechallenge after grade 3 ALT elevation, only two (23%) required re-interruption due to repeat grade 3 ALT elevation.
Conclusions
This is the first study to examine hepatic dysfunction caused by CABO+NIVO in Japanese patients. The incidence of hepatic dysfunction was higher in real-world patients than in global patients found in pivotal phase 3 trials. Cabozantinib appeared to be a major cause of hepatic dysfunction since dose reduction or interruption of cabozantinib without the use of corticosteroids resolved hepatotoxicity. In addition, additional care should be taken when treating female or obese patients with CABO+NIVO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi, Tokyo, 123-8558, Japan.
- Department of Urology, Tokiwakai Jyoban Hospital, 57 Kaminodai, Jyoban Kamiyunagayamachi, Iwaki, Fukushima, 972-8322, Japan.
ORCID-Profile: Tsunenori Kondo
Zitieren
APA
Horiuchi, T., Nishimura, K., Nakamura, K., Nemoto, Y., Ishiyama, Y., Katsurayama, N., Toki, D., Kobayashi, H., & Kondo, T. (2025). High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf070
Vancouver
Horiuchi T, Nishimura K, Nakamura K, Nemoto Y, Ishiyama Y, Katsurayama N, et al. High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf070
BibTeX
@article{Horiuchi2025,
author = {Horiuchi, Toshihide and Nishimura, Koichi and Nakamura, Kazutaka and Nemoto, Yuki and Ishiyama, Yudai and Katsurayama, Nanaka and Toki, Daisuke and Kobayashi, Hirohito and Kondo, Tsunenori},
title = {High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinoma},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf070}
}
EUVIMED